InsidersTradesSigma
Follow the Deciphera Pharmaceuticals, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Deciphera Pharmaceuticals, Inc. has logged 78 reports. The latest transaction was disclosed on 11 June 2024 (Attribution). Among the most active insiders: Sherman Matthew L. All data is accessible without an account.
78
Insider Decl.
n/a
Thresholds
€42m
4 ops.
Buy Volume
€1m
30 ops.
Sell Volume
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 June 2024
Declarations78 total
34,157 sharesCommon StockSEC:0000950170-24-072223:0
10,000 sharesCommon StockSEC:0000950170-24-072218:0
11,000 sharesCommon StockSEC:0000950170-24-072208:0
20,163 sharesCommon StockSEC:0000950170-24-072220:0
20,163 sharesCommon StockSEC:0000950170-24-072209:0
34,157 sharesCommon StockSEC:0000950170-24-072221:0
25,913 sharesCommon StockSEC:0000950170-24-072214:0
286,075 sharesCommon StockSEC:0000950170-24-072196:0
48,136 shares@ US$0.010.0% of flowCommon StockSEC:0001493152-24-015800:0
17,275 shares0Common StockSEC:0000950170-24-017085:0
17,275 shares0Common StockSEC:0000950170-24-017091:0
9,725 shares0Common StockSEC:0000950170-24-017084:0
9,725 shares0Common StockSEC:0000950170-24-017087:0
17,275 shares0Common StockSEC:0000950170-24-017089:0
914,001 shares@ US$0.010.0% of flowCommon StockSEC:0001493152-24-005709:0
1,624 shares@ US$14.469821.3% of flowCommon StockSEC:0000950170-24-005391:0
1,624 shares@ US$14.46977.0% of flowCommon StockSEC:0000950170-24-005388:0
2,435 shares@ US$14.469822.8% of flowCommon StockSEC:0000950170-24-005389:0
2,435 shares@ US$14.46978.7% of flowCommon StockSEC:0000950170-24-005393:0
5,576 sharesCommon StockSEC:0000950170-23-070383:0
5,576 sharesCommon StockSEC:0000950170-23-070385:0
62,500 sharesCommon StockSEC:0000950170-23-070386:0
8,244 sharesCommon StockSEC:0000950170-23-070382:0
8,244 sharesCommon StockSEC:0000950170-23-070384:0
17,801 shares@ US$12.569866.9% of flowCommon StockSEC:0000950170-23-067324:0
25 of 78 declarations
关于 Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. 是一家总部位于美国的生物制药公司，专注于肿瘤学。该公司成立于 2003 年，围绕一个专有的药物发现平台构建，旨在靶向激酶信号通路并开发用于治疗具有重大未满足医疗需求的癌症的药物。对于讲法语的投资者而言，Deciphera 应被视为一家专业生物技术公司，而非一家广泛的制药集团：其价值主张一直以精准肿瘤学、临床差异化和监管执行为核心。该公司与美国市场相关联，曾在纳斯达克交易，总部位于美国马萨诸塞州沃尔瑟姆。([deciphera.com](https://www.deciphera.com/about?utm_source=openai)) 在商业方面，Deciphera 的产品组合以 QINLOCK (ripretinib) 为核心，这是一种用于晚期胃肠道间质瘤 (GIST) 的口服疗法，后来又扩展到 ROMVIMZA (vimseltinib)，该药物于 2025 年 2 月获得 FDA 全面批准，用于治疗手术可能加重功能限制或导致严重发病率的有症状腱鞘巨细胞瘤 (TGCT) 成年患者。该批准是公司内部研发引擎的重要验证事件，并展示了其将分子从发现阶段推进到后期开发并进入市场的能力。该公司还继续推进其他项目，包括 tirabrutinib，FDA 于 2026 年接受了其在血液学/肿瘤学领域的 NDA。([deciphera.com](https://www.deciphera.com/news/us-fda-grants-full-approval-decipheras-romvimzatm-vimseltinib-treatment-symptomatic?utm_source=openai)) 从竞争角度来看，Deciphera 在竞争激烈的肿瘤学领域运营，差异化取决于临床疗效、安全性、便利性以及获得监管和报销支持的能力。其战略是专注于选定的罕见或未满足需求的适应症，如果临床数据强劲，这可以创造有吸引力的商业机会。该公司的地理足迹主要在美国，通过合作伙伴关系和在美国以外（包括欧洲）的监管备案来支持国际开发和商业化工作。([fintel.io](https://fintel.io/doc/sec-deciphera-pharmaceuticals-inc-1654151-10k-2024-february-07-19760-2425?utm_source=openai)) 最近的一个重要里程碑重塑了股权故事：Deciphera 被 Ono Pharmaceutical 收购，并于 2024 年 6 月宣布完成。该公司表示，交易完成后，Deciphera 股票停止在纳斯达克交易。对于投资者而言，这意味着当前对 Deciphera 的提及最好在历史或公司结构背景下理解，而不是作为一家活跃的独立上市公司。Deciphera 现在作为 Ono 集团旗下的全资子公司运营，这改变了人们对内部人备案、估值和独立市场分析的解读方式。([deciphera.com](https://www.deciphera.com/news/deciphera-pharmaceuticals-be-acquired-ono-pharmaceutical-24-billion?utm_source=openai))
